SCHEMBL7065589

SCHEMBL7065589

Cc1cc(N2CCCC2)n2nc(-c3ccccc3)cc2n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.63
HSD17B10 Q99714 5/20 0.63
MAPK1 P28482 4/20 0.63
GAA P10253 3/20 0.63
NPC1 O15118 4/20 0.62
RAB9A P51151 4/20 0.62
MAPT P10636 5/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
HPGD P15428 9/20 0.60
ABCB1 P08183 3/20 0.60
LMNA P02545 4/20 0.60
HTT P42858 3/20 0.60
KMT2A Q03164 3/20 0.60
MEN1 O00255 1/20 0.60
ALDH1A1 P00352 6/20 0.59
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
RELA Q04206 1/20 0.59
TAAR1 Q96RJ0 1/20 0.58
ABCG2 Q9UNQ0 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7067639 0.97 KDM4E (0.63) KDM4EHSD17B10MAPK1GAANPC1
SCHEMBL7065606 0.88 ABCB1 (0.61) KDM4EHSD17B10MAPK1GAANPC1
SCHEMBL7062668 0.87 HPGD (0.65) KDM4EHSD17B10MAPK1GAANPC1
SCHEMBL7067515 0.87 KDM4E (0.68) KDM4EHSD17B10MAPK1GAAMAPT
SCHEMBL7061181 0.86 NPC1 (0.64) KDM4EHSD17B10MAPK1GAANPC1
SCHEMBL7066706 0.86 KDM4E (0.50) KDM4EHSD17B10MAPK1GAANPC1
SCHEMBL7066787 0.85 NPC1 (0.63) KDM4EHSD17B10MAPK1GAANPC1
SCHEMBL7067977 0.85 ABCB1 (0.57) KDM4EHSD17B10MAPK1GAANPC1
SCHEMBL25973951 0.84 MAPK8 (0.65) KDM4EHSD17B10MAPK1GAANPC1
SCHEMBL7061177 0.83 KDM4E (0.52) KDM4EHSD17B10MAPK1GAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030100546-A1 Neuropeptide Y antagonists ELLIOTT RICHARD L (US) 2003-05-29 US claimed
US-20020061897-A1 Neuropeptide Y antagonists ELLIOTT RICHARD L (US) 2002-05-23 US claimed
US-6649759-B2 Pyrazolo(1,5-a)pyrimidine derivatives; treating feeding, cardiovascular and psychological disorders PFIZER INC. 2003-11-18 US disclosed
US-20030100546-A1 Neuropeptide Y antagonists ELLIOTT RICHARD L (US) 2003-05-29 US disclosed
US-20020061897-A1 Neuropeptide Y antagonists ELLIOTT RICHARD L (US) 2002-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100546-A1 Neuropeptide Y antagonists NPY1R, NPY2R, GIPR KDM4E 3423/4885HSD17B10 1433/4885MAPK1 704/4885
US-20020061897-A1 Neuropeptide Y antagonists NPY1R, NPY2R, GIPR KDM4E 3423/4885HSD17B10 1433/4885MAPK1 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.